SinoPep Biotechnology (Changzhou) Co., Ltd.

The counter-ion content is on the certificate as a figure with units, and it is there without my having asked. Most of my folder reports area percent and stops, which leaves the mass of peptide in the vial as an exercise for the reader.

Gradient table, column chemistry and detection wavelength printed alongside the figure. A purity value without its method is not a measurement and I have stopped treating one as though it were.

Blind submission to Janoshik, origin withheld. 98.9% against 98.6% declared. Documentation practice rather than a single purity figure is the substance of this.

Repeat purchase of one line eleven months after the first, both determined on the same declared method, results a tenth of a point apart. That is the comparison I want and it is almost never available.

Content is reported separately from chromatographic purity. Two different quantities, correctly separated. This sounds like the floor and it is not.

Related substances came as an itemised table with retention times rather than a single total. A total conceals whether one impurity or twelve produced it.

Asked for a chromatogram against a lot bought fourteen months earlier. It arrived the following working day and nobody asked why I wanted it.

Water by Karl Fischer and an appearance statement, both on the document as issued. Trivial determinations; carrying them unprompted is a reliable signal about the operation behind the paper.

Five lots of one line across ten months, purity band under a point wide. Consistency across lots is worth more to me than the best single figure in a file.

Weighed eleven vials from one consignment against declared fill. All inside two per cent. Fill uniformity is harder than purity and discussed a tenth as often.

No adverse finding on material. A written quotation for a non-catalogue sequence took three working days where catalogue enquiries were answered the same afternoon. Recording it as a planning matter.

The lot identifier printed on the unit is small. I photograph the carton on receipt now, which is a habit this supplier gave me rather than a fault I can pin on them.

Asked which resin a line was assembled on and had an answer rather than a referral. That question is only answerable where synthesis is performed in house.

Transit from Changzhou tracked without a dead interval. Unscanned intervals are what make a transit estimate useless and there were none.

The declared figure has been the conservative one on every submission in this file. The direction of the discrepancy is the part that matters.

Certificate, vial and invoice carried the same lot identifier across three consecutive orders. That is a records system rather than luck.

They quoted a sequence two other suppliers declined to respond about, with a purity target and a timeline, and both held.

Independent determination through Medutest agreed with the declared figure within the combined uncertainty of the two methods. Agreement within uncertainty is the correct standard.

Second certificate produced against a lot purchased the previous year without escalation. Retention is either a system or a favour and this reads as a system.

Not affiliated. Two purchases, one independent determination, both unremarkable. Submitting because the file was thin when I was deciding.

Peptide content by weight was reported on request with the method named. It was not on the certificate as standard and I would prefer that it were.

The counter-ion figure changed the arithmetic on my dose calculation by more than the purity figure did. I had not previously appreciated that and this file is why.

Regional stock question answered before I ordered, and the lane quoted matched the lane delivered. Changzhou is inland and the two lanes are not close.

Three orders, no variance in documentation between them. Nothing here is remarkable, which is the finding.